{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:33:53Z","timestamp":1786988033846,"version":"build-2736575974"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T00:00:00Z","timestamp":1618099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ejca.2021.04.005","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T20:16:21Z","timestamp":1620677781000},"page":"136-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response"],"prefix":"10.1016","volume":"151","author":[{"given":"Olga","family":"Bogatyrova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5294-7808","authenticated-orcid":false,"given":"Johanna S.M.","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith M.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Sanderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Backman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Botling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7402-138X","authenticated-orcid":false,"given":"Hans","family":"Brunnstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3790-3986","authenticated-orcid":false,"given":"Pinja","family":"Kurppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linn\u00e9a","family":"La Fleur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3783-7256","authenticated-orcid":false,"given":"Carina","family":"Strell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Wilm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Esdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1210-5961","authenticated-orcid":false,"given":"Patrick","family":"Micke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejca.2021.04.005_bib1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrclinonc.2010.64","article-title":"Targeted therapy in non-small-cell lung cancer\u2013is it becoming a reality?","volume":"7","author":"Janku","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.005_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2020.04.019","article-title":"Conceptual framework for precision cancer medicine in Germany: consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy","volume":"135","author":"Westphalen","year":"2020","journal-title":"Eur J Canc"},{"issue":"10","key":"10.1016\/j.ejca.2021.04.005_bib3","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.ejca.2010.04.002","article-title":"The biology and treatment of EML4-ALK non-small cell lung cancer","volume":"46","author":"Sasaki","year":"2010","journal-title":"Eur J Canc"},{"issue":"9","key":"10.1016\/j.ejca.2021.04.005_bib4","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1158\/1078-0432.CCR-13-1591","article-title":"Beyond histology: translating tumor genotypes into clinically effective targeted therapies","volume":"20","author":"Meador","year":"2014","journal-title":"Clin Canc Res"},{"issue":"5777","key":"10.1016\/j.ejca.2021.04.005_bib5","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1126\/science.1125951","article-title":"Targeting tyrosine kinases in cancer: the second wave","volume":"312","author":"Baselga","year":"2006","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.ejca.2021.04.005_bib6","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1016\/S1470-2045(15)00077-7","article-title":"Genomic alterations in lung adenocarcinoma","volume":"16","author":"Devarakonda","year":"2015","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2021.04.005_bib7","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.ejca.2015.06.107","article-title":"Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma","volume":"51","author":"Preusser","year":"2015","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.04.005_bib8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2018.11.030","article-title":"Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study","volume":"109","author":"Lai","year":"2019","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.04.005_bib9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2019.07.024","article-title":"Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours","volume":"120","author":"Jones","year":"2019","journal-title":"Eur J Canc"},{"issue":"1","key":"10.1016\/j.ejca.2021.04.005_bib10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ctrv.2011.04.001","article-title":"Targeted therapies for advanced non-small-cell lung cancer: current status and future implications","volume":"38","author":"Custodio","year":"2012","journal-title":"Canc Treat Rev"},{"issue":"9","key":"10.1016\/j.ejca.2021.04.005_bib11","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion-positive\u00a0non-small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2021.04.005_bib12","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1200\/JCO.2019.37.15_suppl.9008","article-title":"Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC)","volume":"37","author":"Gainor","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.005_bib13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2020.06.023","article-title":"KRAS inhibition in non-small cell lung cancer: past failures, new findings and upcoming challenges","volume":"137","author":"Passiglia","year":"2020","journal-title":"Eur J Canc"},{"issue":"7781","key":"10.1016\/j.ejca.2021.04.005_bib14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ejca.2021.04.005_bib15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.canlet.2016.05.017","article-title":"Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein","volume":"380","author":"Wang","year":"2016","journal-title":"Canc Lett"},{"issue":"2","key":"10.1016\/j.ejca.2021.04.005_bib16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Canc"},{"issue":"4","key":"10.1016\/j.ejca.2021.04.005_bib17","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-19-2035","article-title":"Facts and new hopes on selective FGFR inhibitors in solid tumors","volume":"26","author":"Facchinetti","year":"2020","journal-title":"Clin Canc Res"},{"issue":"4","key":"10.1016\/j.ejca.2021.04.005_bib18","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2021.04.005_bib19","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"62","key":"10.1016\/j.ejca.2021.04.005_bib20","doi-asserted-by":"crossref","first-page":"62ra93","DOI":"10.1126\/scitranslmed.3001451","article-title":"Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer","volume":"2","author":"Weiss","year":"2010","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.ejca.2021.04.005_bib21","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","article-title":"FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer","volume":"70","author":"Turner","year":"2010","journal-title":"Canc Res"},{"issue":"10","key":"10.1016\/j.ejca.2021.04.005_bib22","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.jtho.2019.05.041","article-title":"SWOG S1400D (NCT02965378), a phase II study of the fibroblast growth factor receptor inhibitor AZD4547 in previously treated patients with fibroblast growth factor pathway-activated stage IV squamous cell lung cancer (Lung-MAP substudy)","volume":"14","author":"Aggarwal","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2021.04.005_bib23","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1200\/JCO.19.02630","article-title":"Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: results from the NCI-MATCH trial (EAY131) subprotocol W","volume":"38","author":"Chae","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.04.005_bib24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","volume":"35","author":"Nogova","year":"2017","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2021.04.005_bib25","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1158\/1078-0432.CCR-17-0645","article-title":"A phase Ib open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers","volume":"23","author":"Paik","year":"2017","journal-title":"Clin Canc Res"},{"issue":"2 Pt B","key":"10.1016\/j.ejca.2021.04.005_bib26","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.canlet.2014.10.032","article-title":"Prognostic impact of COX-2 in non-small cell lung cancer: a comprehensive compartment-specific evaluation of tumor and stromal cell expression","volume":"356","author":"Mattsson","year":"2015","journal-title":"Canc Lett"},{"issue":"1","key":"10.1016\/j.ejca.2021.04.005_bib27","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/1078-0432.CCR-12-1139","article-title":"Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation","volume":"19","author":"Botling","year":"2013","journal-title":"Clin Canc Res"},{"issue":"6","key":"10.1016\/j.ejca.2021.04.005_bib28","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jtho.2016.01.020","article-title":"The impact of the fourth edition of the WHO classification of lung tumours on histological classification of\u00a0resected pulmonary NSCCs","volume":"11","author":"Micke","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2021.04.005_bib29","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/PAI.0000000000000235","article-title":"Various antibody clones of Napsin A, thyroid transcription factor 1, and p40 and comparisons with cytokeratin 5 and p63 in histopathologic Diagnostics of non-small cell lung carcinoma","volume":"24","author":"Tran","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.ejca.2021.04.005_bib30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2020.06.002","article-title":"ASCL1 promotes tumor progression through cell-autonomous signaling and immune modulation in a subset of lung adenocarcinoma","volume":"489","author":"Miyashita","year":"2020","journal-title":"Canc Lett"},{"issue":"4","key":"10.1016\/j.ejca.2021.04.005_bib31","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/path.5026","article-title":"Multispectral imaging for quantitative and compartment-specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients","volume":"244","author":"Mezheyeuski","year":"2018","journal-title":"J Pathol"},{"issue":"11","key":"10.1016\/j.ejca.2021.04.005_bib32","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/modpathol.2012.102","article-title":"Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer","volume":"25","author":"Schildhaus","year":"2012","journal-title":"Mod Pathol"},{"issue":"11","key":"10.1016\/j.ejca.2021.04.005_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187246","article-title":"Integrative analysis of genome-wide gene copy number changes and gene expression in non-small cell lung cancer","volume":"12","author":"Jabs","year":"2017","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.ejca.2021.04.005_bib34","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86837","article-title":"Profiling cancer testis antigens in non-small-cell lung cancer","volume":"1","author":"Djureinovic","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejca.2021.04.005_bib35","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/1471-2105-11-276","article-title":"Comparison of scores for bimodality of gene expression distributions and genome-wide evaluation of the prognostic relevance of high-scoring genes","volume":"11","author":"Hellwig","year":"2010","journal-title":"BMC Bioinf"},{"key":"10.1016\/j.ejca.2021.04.005_bib36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.lungcan.2019.01.003","article-title":"Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11","volume":"130","author":"La Fleur","year":"2019","journal-title":"Lung Canc"},{"key":"10.1016\/j.ejca.2021.04.005_bib37","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.12688\/f1000research.12223.1","article-title":"Recount workflow: accessing over 70,000 human RNA-seq samples with Bioconductor","volume":"6","author":"Collado-Torres","year":"2017","journal-title":"F1000Res"},{"issue":"2","key":"10.1016\/j.ejca.2021.04.005_bib38","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ccell.2018.07.001","article-title":"Comprehensive analysis of alternative splicing across tumors from 8,705 patients","volume":"34","author":"Kahles","year":"2018","journal-title":"Canc Cell"},{"issue":"4","key":"10.1016\/j.ejca.2021.04.005_bib39","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.ejca.2021.04.005_bib40","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and treatment of cancer, National cancer Institute of the United States, National cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"Database issue","key":"10.1016\/j.ejca.2021.04.005_bib41","doi-asserted-by":"crossref","first-page":"D163","DOI":"10.1093\/nar\/gkq1107","article-title":"miRTarBase: a database curates experimentally validated microRNA-target interactions","volume":"39","author":"Hsu","year":"2011","journal-title":"Nucleic Acids Res"},{"issue":"13 Supplement","key":"10.1016\/j.ejca.2021.04.005_bib42","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1158\/1538-7445.AM2019-4853","article-title":"Abstract 4853: M6123 is an ADCC-enhanced and selective monovalent antagonist of FGFR1 showing antitumor activity in preclinical lung cancer models","volume":"79","author":"Esdar","year":"2019","journal-title":"Canc Res"},{"key":"10.1016\/j.ejca.2021.04.005_bib43","doi-asserted-by":"crossref","first-page":"115215","DOI":"10.1016\/j.taap.2020.115215","article-title":"A novel monovalent FGFR1 antagonist: preclinical safety profiles in rodents and non-human primates","volume":"406","author":"Yu","year":"2020","journal-title":"Toxicol Appl Pharmacol"},{"issue":"24","key":"10.1016\/j.ejca.2021.04.005_bib44","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1158\/1078-0432.CCR-12-2694","article-title":"Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models","volume":"18","author":"Zhang","year":"2012","journal-title":"Clin Canc Res"},{"issue":"1","key":"10.1016\/j.ejca.2021.04.005_bib45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/hmg\/ddv441","article-title":"Multikinase activity of fibroblast growth factor receptor (FGFR) inhibitors SU5402, PD173074, AZD1480, AZD4547 and BGJ398 compromises the use of small chemicals targeting FGFR catalytic activity for therapy of short-stature syndromes","volume":"25","author":"Gudernova","year":"2016","journal-title":"Hum Mol Genet"},{"issue":"12","key":"10.1016\/j.ejca.2021.04.005_bib46","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1158\/1078-0432.CCR-13-3060","article-title":"FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies","volume":"20","author":"Wynes","year":"2014","journal-title":"Clin Canc Res"},{"issue":"27","key":"10.1016\/j.ejca.2021.04.005_bib47","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1038\/onc.2015.426","article-title":"Co-active receptor tyrosine kinases mitigate the effect of\u00a0FGFR inhibitors in FGFR1-amplified lung cancers with low\u00a0FGFR1 protein expression","volume":"35","author":"Kotani","year":"2016","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.ejca.2021.04.005_bib48","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1158\/1535-7163.MCT-17-0174","article-title":"Cisplatin increases sensitivity to FGFR inhibition in patient-derived xenograft models of lung squamous cell carcinoma","volume":"16","author":"Weeden","year":"2017","journal-title":"Mol Canc Therapeut"},{"issue":"10","key":"10.1016\/j.ejca.2021.04.005_bib49","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(19)30412-7","article-title":"Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Schuler","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2021.04.005_bib50","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00428-012-1250-y","article-title":"FGFR1 expression and gene copy numbers in human lung cancer","volume":"461","author":"Kohler","year":"2012","journal-title":"Virchows Arch"},{"issue":"4","key":"10.1016\/j.ejca.2021.04.005_bib51","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/ijc.28090","article-title":"Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer","volume":"133","author":"Pros","year":"2013","journal-title":"Int J Canc"},{"issue":"2","key":"10.1016\/j.ejca.2021.04.005_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149628","article-title":"Characterization of FGFR1 locus in sqNSCLC reveals a broad and heterogeneous amplicon","volume":"11","author":"Rooney","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejca.2021.04.005_bib53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/cdd.2017.159","article-title":"BCL2 and miR-15\/16: from\u00a0gene discovery to treatment","volume":"25","author":"Pekarsky","year":"2018","journal-title":"Cell Death Differ"},{"issue":"1","key":"10.1016\/j.ejca.2021.04.005_bib54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-018-0594-4","article-title":"MiR-16 regulates the pro-tumorigenic potential of lung fibroblasts through the inhibition of HGF production in an FGFR-1- and MEK1-dependent manner","volume":"11","author":"Andriani","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ejca.2021.04.005_bib55","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.canlet.2018.02.015","article-title":"The Hippo\/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer","volume":"423","author":"Lu","year":"2018","journal-title":"Canc Lett"},{"issue":"8","key":"10.1016\/j.ejca.2021.04.005_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105524","article-title":"Prognostic value of FGFR gene amplification in patients with different types of cancer: a systematic review and meta-analysis","volume":"9","author":"Chang","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ejca.2021.04.005_bib57","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jtho.2020.12.010","article-title":"Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73\/adenosine pathway as a potential therapeutic target","volume":"16","author":"Le","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2021.04.005_bib58","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-020-02840-0","article-title":"Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscape","author":"Song","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.ejca.2021.04.005_bib59","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.athoracsur.2020.05.041","article-title":"Clinical impacts of EGFR mutation status: analysis of 5780 surgically resected lung cancer cases","volume":"111","author":"Suda","year":"2021","journal-title":"Ann Thorac Surg"},{"issue":"22","key":"10.1016\/j.ejca.2021.04.005_bib60","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1158\/1078-0432.CCR-18-0163","article-title":"TP53, STK11, and EGFR mutations predict tumor immune profile and the response to anti-PD-1 in lung adenocarcinoma","volume":"24","author":"Biton","year":"2018","journal-title":"Clin Canc Res"},{"issue":"5","key":"10.1016\/j.ejca.2021.04.005_bib61","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/0008-5472.CAN-15-1439","article-title":"STK11\/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment","volume":"76","author":"Koyama","year":"2016","journal-title":"Canc Res"},{"issue":"10","key":"10.1016\/j.ejca.2021.04.005_bib62","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/beta-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin Canc Res"},{"issue":"5","key":"10.1016\/j.ejca.2021.04.005_bib63","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Canc Cell"},{"issue":"11","key":"10.1016\/j.ejca.2021.04.005_bib64","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1356145","article-title":"EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer","volume":"6","author":"Dong","year":"2017","journal-title":"OncoImmunology"},{"issue":"43","key":"10.1016\/j.ejca.2021.04.005_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aav3937","article-title":"Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer","volume":"5","author":"Sugiyama","year":"2020","journal-title":"Sci Immunol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921002264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921002264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:31:51Z","timestamp":1760733111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921002264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":65,"alternative-id":["S0959804921002264"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.04.005","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}